3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
5
Thoracic
2
Gynecologic
2
Plasma cell
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Melanoma
3
Carcinoma, Non-Small-Cell Lung
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Merkel Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
29
Nivolumab
12
atezolizumab
7
Cyclophosphamide
7
Paclitaxel
5
Ipilimumab
5
Docetaxel
5
fludarabine
4
avelumab
4
Cisplatin
4
Carboplatin
4
Bevacizumab
4
cemiplimab
3
Leucovorin
3
Gemcitabine
3
Drug Therapy
3
utomilumab
2
ulixertinib
2
tislelizumab
2
poly ICLC
2
milademetan
2
epacadostat
2
durvalumab
2
budigalimab
2
aldesleukin
2
Trastuzumab
2
Standard of Care
2
Specimen Handling
2
Sirolimus
2
Pemetrexed
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
zimberelimab
×
Dermatologic
×
Clear all
NCT04772989
2025-08-28
ARC-12
Arcus Biosciences, Inc.
Phase 1
Completed
94 enrolled